Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 272 results for nursing

  1. Care of dying adults in the last days of life (QS144)

    This quality standard covers the clinical care of adults (aged 18 and over) who are dying, during the last 2 to 3 days of life. It describes high-quality care in priority areas for improvement.

  2. What is the effectiveness of using defined approaches or decision support toolkits to determine nursing staff requirements and skill mix on acute adult inpatient wards in the UK?

    effectiveness of using defined approaches or decision support toolkits to determine nursing staff requirements and skill mix on acute...

  3. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    In development Reference number: GID-TA11052 Expected publication date:  17 February 2027

  4. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    In development Reference number: GID-TA11100 Expected publication date:  13 May 2027

  5. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    In development Reference number: GID-TA11956 Expected publication date:  28 January 2027

  6. Intermediate care including reablement (NG74)

    This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.

  7. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]

    In development Reference number: GID-TA11341 Expected publication date:  02 December 2026

  8. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    In development Reference number: GID-TA11886 Expected publication date:  13 May 2027

  9. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.

  10. Fractures (complex): assessment and management (NG37)

    This guideline covers assessing and managing pelvic fractures, open fractures and severe ankle fractures (known as pilon fractures and intra-articular distal tibia fractures) in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It aims to reduce deaths and long-term health problems by improving the quality of emergency and urgent care.

  11. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

  12. Vaccine uptake in under 19s (QS145)

    This quality standard covers increasing vaccine uptake among children and young people aged under 19 in groups and settings that have low immunisation coverage. It describes high-quality care in priority areas for improvement.

  13. Stroke and transient ischaemic attack in over 16s. Patient decision aid on decompressive hemicraniectomy surgery in people over 60

    to their own bodily needs or walk without help. They might need constant nursing care and attention, not be able to get out of bed, not...

  14. Stroke and transient ischaemic attack in over 16s. Patient decision aid on decompressive hemicraniectomy surgery in people under 60

    to their own bodily needs or walk without help. They might need constant nursing care and attention, not be able to get out of bed, not...

  15. Community-based models of flu vaccination:- What models of community-based flu vaccination provision (for example, community pharmacies, community nursing and midwifery teams and outreach services) are effective and cost-effective for increasing uptake in eligible groups?

    flu vaccination provision (for example, community pharmacies, community nursing and midwifery teams and outreach services) are effective...